Artificial Intelligence Meets Psychedelics – The Daily Dive feat Fabio Chianelli

Today on the Daily Dive, Fabio Chianelli, CEO of PharmaTher Inc (CSE: PHRM) sits down with our host Cassandra Leah to discuss the company as well as the psychedelic space in general. Within, he discusses his outlook for the growing psychedelic renaissance as well as the direction that PharmaTher is headed in terms of research and development.

Pharmather is one of the latest firms to begin trading on the Canadian Securities Exchange, with a focus on the psychedelic space. The company works to combine artificial intelligence with research and development to develop solutions for unmet medical needs with these psychedelic compounds. The company is currently focused on the brain and nervous system, with a number of target conditions already identified.

Check out the full interview below.


FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Musk’s Ketamine Use Is Apparently In Everyone’s Best Interest

Tesla Inc (Nasdaq: TSLA) CEO Elon Musk believes that his prescribed use of ketamine is...

Tuesday, March 19, 2024, 05:12:50 PM

Pharmather Appoints Dr Alberto J Espay As Scientific Advisor

Pharmather Inc (CSE: PHRM) has appointed a prolific Parkinson’s researcher to its team of scientific...

Wednesday, November 11, 2020, 08:29:13 AM

Pharmather Acquires Exclusive License For Ketamine Treatment Against Parkinson’s Disease

Pharmather Inc (CSE: PHRM) this morning announced that it has entered into an exclusive licensing...

Thursday, October 15, 2020, 09:02:27 AM

PharmaTher Submits For Phase 2 Clinical Trial With FDA

PharmaTher Holdings (CSE: PHRM) is looked to complete a phase two clinical trial. The company...

Tuesday, April 20, 2021, 07:38:21 AM

Revive Therapeutics Enters LOI To Acquire Psilocybin Program From PharmaTher

Revive Therapeutics (CSE: RVV) this morning announced that it has entered into a letter of...

Monday, December 21, 2020, 08:38:29 AM